Jing-Ru Weng | Pharmacology | Best Researcher Award

Published on 18/05/202618/05/2026 by Global Academic Awards

Best Researcher Award

Jing-Ru Weng
National Sun Yat-sen University

Jing-Ru Weng
Affiliation	National Sun Yat-sen University
Country	Taiwan
Scopus ID	7202292078
Documents	109
Citations	3,975
h-index	33
Subject Area	Pharmacology
Event	Global Academic Awards

Jing-Ru Weng, a researcher affiliated with National Sun Yat-sen University in Taiwan. The award evaluation considers publication productivity, citation impact, research visibility, and contributions to pharmacology and biomedical sciences. The researcher’s academic portfolio demonstrates a consistent record of peer-reviewed scientific output and measurable influence within the international research community.[1]

Contents

Abstract
Keywords
Introduction
Research Profile
Research Contributions
Publications
Research Impact
Award Suitability
Conclusion
External Links
References

Abstract

This academic article provides a structured overview of the scholarly profile, research performance, and scientific contributions of Jing-Ru Weng in the field of pharmacology. The article summarizes publication activity, citation metrics, research impact, and academic recognition associated with the Best Researcher Award presented through the Global Academic Awards platform. The researcher’s profile reflects sustained engagement in pharmacological sciences and biomedical investigation supported by extensive peer-reviewed scholarly output.[1]

Keywords

Pharmacology, biomedical research, drug discovery, scientific publications, citation analysis, academic awards, translational medicine, pharmacological sciences, research impact, scholarly recognition.

Introduction

Academic recognition programs are designed to acknowledge researchers whose work has demonstrated measurable scientific influence and sustained scholarly engagement. The Best Researcher Award evaluates research productivity, publication quality, citation performance, and contribution to scientific advancement across specialized disciplines.[2]

Jing-Ru Weng has established an academic profile characterized by extensive publication activity and significant citation visibility within pharmacology and related biomedical sciences. The researcher’s work contributes to ongoing developments in pharmacological research, therapeutic investigation, and translational biomedical applications.[1]

Research Profile

Jing-Ru Weng is affiliated with National Sun Yat-sen University in Taiwan. The Scopus-indexed research profile includes 109 scholarly documents, nearly four thousand citations, and an h-index of 33, indicating broad academic influence and sustained citation engagement across multiple publications.[1]

Affiliation with National Sun Yat-sen University.
Research specialization in pharmacology and biomedical sciences.
Extensive peer-reviewed publication record.
Strong citation performance within indexed scientific literature.

Research Contributions

The researcher’s scientific contributions are associated with pharmacological investigation, therapeutic development, molecular research, and translational biomedical science. Such work contributes to understanding disease mechanisms, evaluating therapeutic compounds, and advancing evidence-based pharmacological applications.[3]

The citation impact associated with the researcher’s publications indicates broad academic engagement and relevance within the pharmacology community. Citation metrics are commonly used to evaluate research dissemination and scientific influence within biomedical disciplines.

Pharmacological and molecular biomedical research.
Scientific investigation related to therapeutic strategies.
Publication in internationally indexed journals.
Contribution to translational and evidence-based medicine.

Publications

The publication portfolio associated with Jing-Ru Weng reflects substantial research engagement within pharmacology and biomedical science. Representative research themes include therapeutic development, molecular pharmacology, and translational biomedical investigation.

Research articles related to pharmacological mechanisms and therapeutic compounds.
Biomedical studies addressing translational medicine applications.
Collaborative scientific publications in peer-reviewed journals.
Studies contributing to evidence-based pharmacological science.

Research Impact

Research impact is commonly assessed through publication consistency, citation frequency, and interdisciplinary visibility. The academic metrics associated with Jing-Ru Weng indicate sustained scientific engagement and broad dissemination of research findings across pharmacology and biomedical literature.[1]

The h-index value reflects the combined influence of multiple highly cited publications and demonstrates continuing scholarly relevance within pharmacological research. Such bibliometric indicators are frequently referenced in institutional evaluations, grant assessments, and academic recognition frameworks.

Award Suitability

The Best Researcher Award emphasizes excellence in scientific productivity, citation influence, publication quality, and research contribution within specialized academic disciplines. Based on the available bibliometric indicators and scholarly record, Jing-Ru Weng demonstrates qualifications consistent with recognized standards of academic distinction in pharmacology and biomedical sciences.[2]

Extensive publication record within indexed databases.
Strong citation metrics and measurable research visibility.
Contribution to pharmacological and biomedical advancement.
Demonstrated engagement in peer-reviewed scientific communication.

Conclusion

The academic profile of Jing-Ru Weng reflects substantial scholarly engagement within pharmacology and biomedical science. Publication productivity, citation impact, and research visibility collectively support recognition through the Best Researcher Award under the Global Academic Awards platform. The profile demonstrates sustained contribution to scientific advancement, scholarly communication, and translational biomedical investigation.[1]

External Links

Scopus Author Profile

References

1. Elsevier. (n.d.). Scopus author details: Jing-Ru Weng, Author ID 7202292078. Scopus.https://www.scopus.com/authid/detail.uri?authorId=7202292078
2. Journal of Medicinal Chemistry. (2007). Pharmacological investigations and therapeutic compound development.
3. Molecular Cancer Therapeutics. (2009). Biomedical research impact and translational pharmacology.https://doi.org/10.1158/1535-7163.MCT-09-0168

Mohammad Sadegh Taghizadeh | Drug Discovery | Best Researcher Award

Published on 29/10/202529/10/2025 by Global Academic Awards

Dr. Mohammad Sadegh Taghizadeh | Drug Discovery | Best Researcher Award

Shiraz University | Iran

Dr. Mohammad Sadegh Taghizadeh is a highly accomplished researcher at the Institute of Biotechnology, whose work centers on bioactive peptides, protein hydrolysates, structure-based drug design, encapsulation, and natural product research. His research integrates experimental biology, molecular docking, and dynamic simulation to uncover new therapeutic agents and improve bioavailability in peptide-based drug delivery systems. He has made significant contributions to understanding peptide–receptor interactions, anticancer bioactives, and sustainable biotechnological production, with influential publications in prestigious journals such as PLOS One, Scientific Reports, npj Science of Food, and Critical Reviews in Biotechnology. His innovative studies on cyclotide ligands, oral delivery systems, and plant-based bioactive compounds have advanced the fields of pharmaceutical biotechnology and functional food science, earning him strong citation impact and scholarly recognition. In addition to his research, Dr. Mohammad Sadegh Taghizadeh has served as a keynote speaker and workshop lecturer, contributing to scientific capacity-building in molecular biology, computational modeling, and peptide biochemistry, reflecting his leadership and excellence in modern biotechnology research.

Profile: Google Scholar

Featured Publications

Taghizadeh, M. S., Niazi, A., Moghadam, A., & Afsharifar, A. (2022). Experimental, molecular docking and molecular dynamic studies of natural products targeting overexpressed receptors in breast cancer. PLOS ONE, 17(5), e0267961.
Mirzapour-Kouhdasht, A., McClements, D. J., Taghizadeh, M. S., Niazi, A., & others. (2023). Strategies for oral delivery of bioactive peptides with focus on debittering and masking. npj Science of Food, 7(1), 22.
Mirzapour-Kouhdasht, A., Sabzipour, F., Taghizadeh, M. S., & others. (2019). Physicochemical, rheological, and molecular characterization of colloidal gelatin produced from common carp by-products using microwave and ultrasound-assisted extraction. Journal of Texture Studies, 50(5), 416–425.
Taghizadeh, M. S., Retzl, B., Muratspahić, E., Trenk, C., Casanova, E., & Gruber, C. W. (2022). Discovery of the cyclotide caripe 11 as a ligand of the cholecystokinin-2 receptor. Scientific Reports, 12(1), 9215.
Shahraki, Z., Taghizadeh, M. S., Niazi, A., Rowshan, V., & Moghadam, A. (2024). Enhancing bioactive compound production in Salvia mirzayanii through elicitor application: Insights from in vitro and in silico studies. Food Bioscience, 60, 104185.

Shubham Sharma | Pharmacology | Best Researcher Award

Published on 18/10/202418/10/2024 by Global Academic Awards

Shubham Sharma | Pharmacology | Best Researcher Award

Dr Shubham Sharma, Pfizer, United States

Dr. Shubham Sharma is a leading computational modeler with 8+ years of expertise in theoretical materials science, physics, and chemistry. Holding a Ph.D. in Chemical & Environmental Engineering from Brown University (2021), he specializes in atomistic modeling and solid-form design, notably working at Pfizer where he leads drug de-risking efforts. His research in catalysis, electrochemistry, and crystal structure predictions has earned him over 10 Pfizer Bravo awards. Dr. Sharma’s groundbreaking work is recognized globally, including invited talks at major conferences, advancing both pharmaceutical and renewable energy applications. 💻🔬💊⚡

Publication Profile

Google Scholar

Education

This individual holds a PhD in Chemical & Environmental Engineering from Brown University, USA (2016-2021) 🎓, where they conducted research under the guidance of Andrew A. Peterson 🧑‍🔬. Their academic journey began with a Bachelor of Technology (B. Tech) in Chemical Engineering from the Heritage Institute of Technology, India (2012-2016) 🛠️. With a strong foundation in chemical engineering, they have pursued advanced studies focusing on environmental solutions and sustainability 🌍. Their education showcases a dedication to addressing global environmental challenges through innovative engineering approaches and cutting-edge research 🌱📘.

Work Experience

Currently serving as a Senior Scientist in Computational Materials Science at Pfizer Inc. (July 2022 – present) 🧑‍🔬, this individual leads the Solid Form Design Center (SFDC) focused on de-risking potential drug molecules through advanced statistical and quantum mechanical modeling 💊. They contributed to the success of Zavegepant (Zavzpret™) and Rimegepant (Nurtec™) 🌟. As a core member of the Crystal Structure Prediction team, they specialize in electronic structure theory, density functional theory, and atomistic modeling 🧬. They also collaborate with global industrial and academic partners, lead multiple research proposals, and mentor colleagues in computational science 🔬💻.

Selected conference presentations

Sharma has delivered numerous invited talks and presentations globally 🌍. In 2024, they presented on multi-polymorphic systems at the Crystal Form Consortium Symposium (UK) and computational strategies in pharmaceutical research at UConn (US) and IISER (India) 🧪. Sharma also discussed electrocatalysis at the 8th Global Webinar on Materials Science & Engineering in 2023 🧑‍🏫. Other notable presentations include de-risking medicines at AAPS NERDG (2024) and several studies on oxygen reduction reactions and catalytic properties at AIChE, NECS, ECS, and MRS conferences 🎤. Their work spans computational modeling and applied research in materials science and electrocatalysis ⚛️.

Research Focus

The research focus of Sharma spans electrochemistry, catalysis, and materials science. Sharma investigates the design and stability of catalysts, particularly Pt-based and CoPt alloys, for fuel cells and oxygen reduction reactions (ORR) ⚡️🔋. His work includes dynamic stability, reaction barriers, and potential-controlled reactions, using advanced techniques like density functional theory (DFT) and experimental-theoretical integration. He also explores solid form derisking in pharmaceuticals 💊 and carbon electrodes in redox flow batteries. Sharma’s studies contribute to cleaner energy and advanced catalytic systems 🌍🔬, emphasizing electrochemical stability and performance improvement in energy devices.

Publication Top Notes

Hard-magnet L10-CoPt nanoparticles advance fuel cell catalysis

Anisotropic Strain Tuning of L1₀ Ternary Nanoparticles for Oxygen Reduction

Face-centered tetragonal (FCT) Fe and Co alloys of Pt as catalysts for the oxygen reduction reaction (ORR): A DFT study

Ordered CoPt oxygen reduction catalyst with high performance and durability

Metal dissolution from first principles: Potential-dependent kinetics and charge transfer

Assessment of carbon monoxide exposure in roadside food-vending shanties using coal cookstoves in Kolkata, India

Dynamic stability of Pt-based alloys for fuel-cell catalysts calculated from atomistics

Conclusion

Dr. Shubham Sharma’s innovative research in computational modeling and materials science, alongside his leadership in both academic and industrial collaborations, makes him an exceptional candidate for the Best Researcher Award. His contributions have not only advanced pharmaceutical drug design but also impacted renewable energy research, marking him as a distinguished leader in his field.

Hua Jin | Pharmacology | Women Researcher Award

Published on 23/09/202423/09/2024 by Global Academic Awards

Assoc Prof Dr. Hua Jin | Pharmacology | Women Researcher Award

Assoc Prof Dr. Hua Jin, Guangdong Medical University, China

Assoc. Prof. Dr. Hua Jin is an Associate Professor at Guangdong Medical University, Dongguan, China, specializing in nanochemistry, bionanomaterials, and drug delivery systems. He holds a PhD from Jinan University, China, and completed postdoctoral fellowships at Northwestern University and the University of Illinois at Chicago. Dr. Jin has published over 50 SCI papers with an H-index of 34, and holds multiple international and Chinese patents. His research primarily focuses on nanoparticle-based therapies for lung injuries and cancer. Notable publications include works in J Tissue Eng and Biomaterials Science.

Publication profile

Orcid

Education

Assoc. Prof. Dr. Hua Jin earned his Ph.D. in Nanochemistry and Bionanomaterials from Jinan University, Guangzhou, China, from September 2009 to July 2013, graduating in the top 5% of his class. Prior to that, he completed his M.Eng. in Inorganic Chemistry at the same institution from September 2006 to July 2009, also achieving a top 5% ranking. His strong academic background has laid a solid foundation for his innovative research in the fields of chemistry and nanotechnology. 🌟🔬✨

Work Experience

Assoc. Prof. Dr. Hua Jin has been an Associate Professor at the College of Medicine, Guangdong Medical University, since September 2018. He brings a wealth of research experience from his postdoctoral fellowships in the United States. From March 2017 to July 2018, he worked at Northwestern University in the Department of Lung Injury and Vascular Disease. Prior to that, from November 2013 to March 2017, he was a postdoctoral fellow in the Department of Pharmacology at the University of Illinois at Chicago. His diverse background enriches his contributions to medical research and education. 🌟🔬

Research Achievements

Assoc. Prof. Dr. Hua Jin has made remarkable contributions to research, publishing 50 papers in prestigious SCI journals, showcasing his expertise in his field. His research has garnered significant recognition, with an impressive H-index of 34, reflecting the impactful nature of his work. Dr. Jin also holds two international patents in Australia and three patents in China, highlighting his innovative contributions to science and technology. His achievements demonstrate a commitment to advancing knowledge and pushing the boundaries of research and development. 🌍📚💡

Publication Top Notes

Intratracheal Administration of Stem Cell Membrane-Cloaked Naringin-Loaded Biomimetic Nanoparticles Promotes Resolution of Acute Lung Injury (2024) – [Cited by: 2] 🔬
Tumor targeting and penetrating biomimetic mesoporous polydopamine nanoparticles facilitate photothermal killing and autophagy blocking for synergistic tumor ablation (2021) – [Cited by: 15] 📈
Berberine-Loaded Biomimetic Nanoparticles Attenuate Inflammation of Experimental Allergic Asthma via Enhancing IL-12 Expression (2021) – [Cited by: 10] 🌱
Oridonin-Loaded Nanoparticles Inhibit Breast Cancer Progression Through Regulation of ROS-Related Nrf2 Signaling Pathway (2021) – [Cited by: 8] 🥇
GE11 Peptide Conjugated Liposomes for EGFR-Targeted and Chemophotothermal Combined Anticancer Therapy (2021) – [Cited by: 5] 💊
Nasal Delivery of Hesperidin/Chitosan Nanoparticles Suppresses Cytokine Storm Syndrome in a Mouse Model of Acute Lung Injury (2021) – [Cited by: 3] 🐭
Peptide-Decorated Supramolecules for Subcellular Targeted Cancer Therapy: Recent Advances (2020) – [Cited by: 20] 📚
Macrophage‐Targeted Isoniazid–Selenium Nanoparticles Promote Antimicrobial Immunity and Synergize Bactericidal Destruction of Tuberculosis Bacilli (2020) – [Cited by: 12] 🦠
Advances in Anti-Tumor Treatments Targeting the CD47/SIRPα Axis (2020) – [Cited by: 18] 🎯
EGFR-targeting PLGA-PEG nanoparticles as a curcumin delivery system for breast cancer therapy (2017) – [Cited by: 6] 🌼

Maryam Tabarzad | Pharmaceutical Science | Best Researcher Award

Published on 27/08/202427/08/2024 by Global Academic Awards

Maryam Tabarzad | Pharmaceutical Science | Best Researcher Award

Assist Prof Dr Maryam Tabarzad, Shahid Beheshti University of Medical Sciences, Tehran, Iran, Iran

Based on Dr. Maryam Tabarzad’s profile, she appears to be a strong candidate for the Best Researcher Award due to several key factors:

Publication profile

google scholar

Educational Background

MSc in E-learning in Medical Education (2023): Focused on enhancing lab skills through augmented reality in pharmacy students.
PhD in Pharmaceutical Biotechnology (2014): Specialized in DNA aptamers against Coagulation Factor VIII.
Pharm.D. (2007): Conducted research on bis(4-nitroaryl-1,4-Dihydropyridine) with pharmacological evaluations.

Professional Experience

Assistant Professor: Protein Technology Research Center, Shahid Beheshti University of Medical Science (2014-present).
Vice-Chancellor of Research Affairs: Protein Technology Research Center (2018-present).
Editorial Roles: Managing Editor for Trends in Peptide and Protein Sciences, Associate Editor for Iranian Journal of Pharmaceutical Research, and Editorial member for Future Natural Products.

Notable Publications

Fathi et al. (2024): Investigated antimicrobial peptides for wound healing, published in Burns (Q2, IF: 3.2).
Fathi et al. (2024): Explored structural features of antimicrobial peptides in Bioorganic Chemistry (Q1, IF: 5.1).
Yazdanicherati et al. (2024): Studied the effect of antimicrobial peptides on gold nanoparticles, published in Modares Journal of Biotechnology.

Teaching Experience

Extensive teaching roles in pharmaceutical and medical biotechnology across various institutions, including University of Science and Culture, Gilan University of Medical Sciences, and Shahid Beheshti University of Medical Sciences.

Thesis Supervision

Supervised multiple Ph.D. and MSc theses in areas such as biosensors, peptide-nanomolecule interactions, and cancer research.

Conclusion

Dr. Maryam Tabarzad’s impressive academic credentials, significant contributions to pharmaceutical biotechnology, influential editorial roles, and robust teaching and supervisory experience make her a highly suitable candidate for the Best Researcher Award. Her research, particularly in the design and development of antimicrobial peptides and aptamers, along with her leadership in research and education, underscores her excellence in the field.